Live price temporarily unavailable.
Jaguar Health (JAGX) is a Health Care company. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $141.5K | $4.36M | $4.42M | $5.78M | $9.38M | $4.33M | $12.0M | $9.76M | $11.7M | $11.5M |
| Growth (year over year) | −45.2% | +2981.6% | +1.3% | +30.8% | +62.5% | −53.8% | +175.8% | −18.4% | +19.8% | −1.5% |
| Gross profit | $89.6K | $3.48M | $1.65M | $1.96M | $6.11M | $2.00M | $9.94M | $7.72M | $9.73M | $7.74M |
| Gross margin | 63.3% | 79.8% | 37.4% | 33.9% | 65.1% | 46.2% | 83.1% | 79.1% | 83.3% | 67.2% |
| Operating income | −$13.6M | −$34.2M | −$30.8M | −$28.9M | −$26.6M | −$40.7M | −$34.4M | −$34.3M | −$30.8M | −$45.9M |
| Operating margin | −9599.8% | −785.3% | −698.0% | −501.3% | −283.9% | −939.1% | −287.8% | −351.3% | −263.8% | −398.8% |
| Net income | −$14.7M | −$22.0M | −$32.1M | −$38.5M | −$33.8M | −$52.6K | −$48.4K | −$41.9K | −$38.5M | −$53.6M |
| Net margin | −10410.9% | −503.7% | −727.9% | −667.3% | −360.2% | −1.2% | −0.4% | −0.4% | −329.3% | −465.4% |
| EPS (diluted) | −$759375.00 | −$18975.00 | −$383175.00 | −$22525.00 | −$150.00 | −$1470.33 | −$603.00 | −$44636.17 | −$130.69 | −$22.97 |
| Balance sheet | ||||||||||
| Cash and equivalents | $951.0K | $520.7K | $2.57M | $3.50M | $8.09M | $17.1M | $5.47M | $6.47M | $8.00M | $968.0K |
| Total assets | $3.56M | $43.6M | $41.0M | $36.4M | $42.8M | $53.3M | $47.5M | $50.8M | $53.4M | $38.3M |
| Total liabilities | $6.02M | $26.4M | $26.7M | $15.8M | $25.6M | $41.4M | $48.8M | $45.9M | $44.4M | $57.0M |
| Long-term debt | $1.82M | $11.0M | — | — | — | — | — | — | — | — |
| Shareholders' equity | −$2.45M | $17.3M | $5.38M | $10.7M | $17.2M | $11.9M | −$1.36M | $4.90M | $6.49M | −$18.7M |
| Cash flow | ||||||||||
| Operating cash flow | −$14.4M | −$9.82M | −$22.7M | −$20.5M | −$15.3M | −$35.0M | −$33.1M | −$33.2M | −$29.4M | −$23.7M |
| Capital expenditure | $104.2K | — | $6.53K | — | $7.00K | $6.00K | $77.0K | — | $16.0K | — |
| Free cash flow | −$14.5M | — | −$22.7M | — | −$15.3M | −$35.0M | −$33.2M | — | −$29.4M | — |
| Share buybacks | — | — | $30 | — | — | — | — | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.11M | $3.51M | $2.21M | $2.98M | $3.08M | $3.23M | $20.3M | $1.23M |
| Growth (year over year) | +10.5% | +52.6% | −5.8% | +9.5% | −0.8% | −7.8% | +815.6% | −58.9% |
| Gross profit | $2.57M | $2.95M | $1.70M | $2.45M | $2.55M | $1.03M | $19.1M | $194.0K |
| Gross margin | 82.6% | 84.1% | 76.7% | 82.3% | 82.7% | 32.0% | 94.3% | 15.8% |
| Operating income | −$7.26M | −$8.16M | −$9.42M | −$8.01M | −$7.24M | −$21.2M | $10.2M | −$7.60M |
| Operating margin | −233.7% | −232.5% | −425.5% | −268.8% | −234.8% | −656.6% | 50.2% | −620.2% |
| Net income | −$9.85M | −$9.92M | −$10.5M | −$10.4M | −$9.50M | −$23.2M | −$7.01M | −$12.7M |
| Net margin | −317.1% | −282.7% | −472.6% | −349.3% | −308.2% | −717.2% | −34.6% | −1036.8% |
| EPS (diluted) | −$26.29 | $1414.10 | −$584.45 | −$358.94 | −$6.28 | $926.70 | −$13.60 | −$15.70 |
| Balance sheet | ||||||||
| Cash and equivalents | $13.3M | $8.00M | $5.69M | $2.21M | $3.53M | $968.0K | $7.28M | $3.79M |
| Total assets | $58.5M | $53.4M | $51.5M | $48.3M | $49.5M | $38.3M | $37.4M | $34.2M |
| Total liabilities | $42.9M | $44.4M | $48.1M | $41.4M | $45.1M | $57.0M | $53.2M | $29.3M |
| Shareholders' equity | $13.1M | $6.49M | $830.0K | $6.88M | $4.36M | −$18.7M | −$15.8M | $4.92M |
| Cash flow | ||||||||
| Operating cash flow | −$6.34M | −$7.83M | −$7.31M | −$6.20M | −$4.69M | −$5.49M | $8.83M | −$5.34M |
| Capital expenditure | $0 | $0 | — | — | — | — | — | — |
| Free cash flow | −$6.34M | −$7.83M | — | — | — | — | — | — |
From Jaguar Health's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Jaguar Health in our feed yet.